Which biomarker is commonly tested to determine eligibility for anti-EGFR therapy in colorectal cancer?
Show answer and explanation
Correct answer: KRAS activating mutation
KRAS mutation testing is essential before anti-EGFR therapy in colorectal cancer. Patients with KRAS mutations do not benefit from these targeted therapies.
Keep practicing
More Precision Medicine questions
- Liquid biopsy primarily involves analysis of:
- Pharmacogenomics studies the relationship between:
- Which gene mutation is commonly targeted in non-small cell lung carcinoma with tyrosine kinase inhibitors?
- Microsatellite instability (MSI) testing is particularly important in:
- Which sequencing approach targets only selected genes of interest?
- PD-L1 expression testing is used to guide therapy in which context?